```html

Craniopharyngioma – A Comprehensive Medical Guide

Overview

Craniopharyngioma is a rare, usually benign (non‑cancerous) brain tumor that arises near the pituitary gland and the hypothalamus at the base of the skull. Although histologically benign, its location makes it potentially life‑threatening because it can compress critical structures that control hormone production, vision, and fluid balance.

• Incidence: Approximately 0.5–2 cases per 1 million people each year worldwide.<sup>1</sup>
• Age distribution: Two peaks – in children (typically 5–14 years) and in adults aged 40–70 years.<sup>2</sup>
• Gender: Slight male predominance in children; no clear gender bias in adults.

Because the tumor grows slowly, many patients experience symptoms for months or even years before diagnosis.

Symptoms

Symptoms reflect the tumor’s pressure on nearby structures. They can be grouped into three main categories: visual, endocrine, and neurological.

Visual disturbances

• Blurred or double vision – caused by pressure on the optic nerves.
• Loss of peripheral (side) vision – classically a “tunnel vision” pattern.
• Reduced visual acuity – may progress to partial blindness if untreated.

Endocrine & metabolic signs

• Growth failure or rapid growth spurts in children (due to pituitary hormone imbalance).
• Weight gain or obesity – hypothalamic involvement can disrupt appetite regulation.
• Fatigue, cold intolerance, low libido – signs of pituitary hormone deficiencies (e.g., cortisol, thyroid, sex hormones).
• Diabetes insipidus – excessive urination and thirst caused by reduced antidiuretic hormone (ADH) production.
• Electrolyte abnormalities – especially low sodium (hyponatremia) if the adrenal axis is affected.

Neurological & general symptoms

• Headache – often described as dull or pressure‑like.
• Nausea & vomiting – especially in the morning, due to increased intracranial pressure.
• Large head circumference in infants (hydrocephalus).
• Memory problems, mood changes, or decreased concentration – hypothalamic dysfunction.
• Sleep disturbances – due to hypothalamic regulation of sleep cycles.

Causes and Risk Factors

The exact cause of craniopharyngioma is not fully understood, but several mechanisms have been identified.

Genetic and developmental factors

• Embryologic remnants: The tumor arises from remnants of Rathke’s pouch, an embryonic structure that forms the anterior pituitary.
• Gene mutations:
  • CTNNB1 (β‑catenin) mutations are common in the adamantinomatous type (more frequent in children).<sup>3</sup>
  • BRAF V600E mutations are seen in the papillary subtype (mainly adults).<sup>4</sup>

Risk factors

• None are strongly modifiable; age is the biggest risk factor because incidence peaks in childhood and middle age.
• Rare familial cases suggest a possible hereditary predisposition, but most cases are sporadic.
• Exposure to radiation (e.g., prior cranial irradiation) has been linked to secondary brain tumors, though a direct link to craniopharyngioma remains weak.

Diagnosis

Diagnosis involves a combination of clinical assessment, imaging, hormonal testing, and sometimes tissue sampling.

Medical history and physical exam

• Detailed symptom review (vision changes, growth patterns, endocrine complaints).
• Neurological exam focusing on visual fields and cranial nerves.
• Endocrine assessment – signs of pituitary hormone deficiency.

Imaging studies

• Magnetic Resonance Imaging (MRI): The gold‑standard test. T1‑ and T2‑weighted images show a suprasellar mass that may have cystic (fluid) and solid components, often with calcifications.
• Computed Tomography (CT): Useful for detecting calcium deposits; often performed when MRI is contraindicated.
• Visual field testing: Formal perimetry to quantify vision loss.

Laboratory evaluation

• Baseline pituitary hormone panel (ACTH, cortisol, TSH, free T4, LH/FSH, estradiol/testosterone, growth hormone, IGF‑1).
• Serum sodium and osmolality if diabetes insipidus is suspected.
• Water deprivation test may be used to confirm central diabetes insipidus.

Pathology (when needed)

In cases where surgical removal is planned, the tumor is sent for histopathology. Two histologic subtypes exist:

• Adamantinomatous: Common in children; shows “wet keratin” and calcifications.
• Papillary: Seen almost exclusively in adults; lacks calcifications.

Treatment Options

Therapy is individualized based on tumor size, location, patient age, and hormone status. A multidisciplinary team (neurosurgeon, endocrinologist, radiation oncologist, ophthalmologist, and neuro‑psychologist) usually manages care.

Surgical approaches

• Transcranial microsurgery: Traditional open craniotomy; provides wide exposure but higher risk of brain injury.
• Endoscopic endonasal approach (EEA): Minimally invasive, through the nose and sphenoid sinus; increasingly preferred for tumors confined to the sellar/suprasellar region.<sup>5</sup>
• Gross‑total resection (GTR): Aim to remove the entire tumor; highest chance of cure but also highest risk of hypothalamic damage.
• Subtotal or partial resection: Leaves residual tumor to protect hypothalamic tissue, followed by adjuvant therapy.

Radiation therapy

• Conformal external beam radiation (EBRT): Traditional technique; delivered over 30–33 sessions.
• Stereotactic radiosurgery (SRS) / Gamma Knife: Precise, high‑dose radiation in 1–5 sessions; suitable for small residual or recurrent tumors.
• Proton beam therapy: Offers superior sparing of surrounding brain tissue; increasingly used in pediatric centers.

Medical management

• Corticosteroid replacement: Hydrocortisone or prednisone if ACTH deficiency is present.
• Thyroid hormone replacement: Levothyroxine for central hypothyroidism.
• Sex hormone replacement: Estrogen/progestin or testosterone as needed.
• Growth hormone (GH) therapy: Considered after tumor control and if no contraindications (e.g., active disease).<sup>6</sup>
• Desmopressin (DDAVP): First‑line for central diabetes insipidus.
• Antiepileptic drugs: Rarely needed, only if seizures occur.

Supportive & lifestyle measures

• Weight‑management programs (dietitian‑guided) to counter hypothalamic obesity.
• Vision rehabilitation services.
• Neuropsychological counseling for memory or mood changes.
• Regular follow‑up imaging (MRI every 6–12 months for the first 5 years, then annually).

Living with Craniopharyngioma

Long‑term management focuses on hormone replacement, monitoring for recurrence, and maintaining quality of life.

Hormone & metabolic care

• Take prescribed hormone replacements exactly as instructed; never miss doses.
• Carry an emergency steroid injection kit if you have adrenal insufficiency.
• Monitor weight weekly; work with a dietitian experienced in hypothalamic obesity.
• Check blood glucose regularly if GH or cortisol therapy is used.

Vision protection

• Schedule ophthalmology exams at least annually.
• Use proper lighting and high‑contrast materials to reduce visual strain.
• Consider low‑vision aids (magnifiers, screen‑reading software) if peripheral vision is compromised.

Neurocognitive and emotional health

• Engage in brain‑stimulating activities (puzzles, reading, learning new skills).
• Seek counseling or support groups—many families benefit from connecting with other craniopharyngioma patients.
• Screen for depression and anxiety; treatment improves adherence to hormone therapy.

Exercise and daily activity

• Low‑impact aerobic exercise (walking, swimming) 150 minutes/week is recommended unless contraindicated by vision problems.
• Strength training can help preserve muscle mass, especially if steroid replacement is used.

Follow‑up schedule

Follow‑up	Frequency
Endocrine labs (pituitary panel)	Every 3–6 months initially, then annually
MRI of sellar region	Every 6–12 months for 5 years, then every 1–2 years
Visual field testing	Yearly or sooner if symptoms change
Neuropsychological assessment	Every 1–2 years or as needed

Prevention

Because craniopharyngioma is largely sporadic and linked to developmental remnants, specific primary prevention strategies are limited.

• No known lifestyle modifications prevent the occurrence of the tumor.
• However, early detection of visual or endocrine changes—especially in children—allows prompt treatment and better outcomes.
• For patients who have received cranial radiation for other conditions, regular neuro‑oncology follow‑up can help identify secondary tumors early.

Complications

If left untreated or inadequately managed, craniopharyngioma can lead to serious, sometimes irreversible problems.

• Permanent vision loss – due to prolonged optic nerve compression.
• Severe hypothalamic obesity – weight gain > 100 % of ideal body weight, difficult to treat.
• Multiple pituitary hormone deficiencies – may cause adrenal crisis, hypothyroidism, infertility.
• Hydrocephalus – buildup of cerebrospinal fluid requiring shunt placement.
• Recurrence – reported in 20–40 % of cases, especially after subtotal resection.<sup>7</sup>
• Secondary malignancies – Rare, associated with prior radiation therapy.
• Neurocognitive decline – Memory and executive function impairment due to hypothalamic or frontal lobe involvement.

When to Seek Emergency Care

---

Sources:
1. Centers for Disease Control and Prevention (CDC). Rare Brain Tumors Overview. https://www.cdc.gov.
2. Mayo Clinic. Craniopharyngioma. https://www.mayoclinic.org.
3. Neoplasia. 2012;14(11):1066‑1075. PMID: 22796197.
4. Journal of Clinical Oncology. 2015;33(15):1802‑1809. PMID: 26229787.
5. Cleveland Clinic. Endoscopic Endonasal Surgery for Craniopharyngioma. https://my.clevelandclinic.org.
6. Endocrine Reviews. 2019;40(5):1035‑1051. PMID: 31008869.
7. Neurosurgery. 2016;78(4):519‑527. PMID: 27408298.

```